A Universal Assembly Platform™ for rapid antibody engineering? We combine bispecificity, multivalent antibodies and ADC in a single drug discovery process. Our CEO Arne Scheu will be presenting our approach at World Bispecific in Boston Oct 2-4. If you are curious to learn more, meet us there or reach out at info@liliumx.com
One month from now AbCellera, Aethon Therapeutics, Alligator Bioscience AB, Amgen, Biocytogen, BioNTech SE, Biosion, Cue Biopharma, FDA, Hinge Bio, LiliumX, Link Immunotherapeutics, Mythic Therapeutics, Inc., Novartis, NYU Grossman School of Medicine, OncoNano Medicine, Inc., OncoOne, Regeneron, Roche, Sanofi, Shenzhen Enduring Biotech, Tavotek Biotherapeutics, Zymeworks Inc. will be taking the stage at the 14th World Bispecific Summit. In-line with the exciting momentum in the bispecific space (including 6 FDA approvals over the past two years), our industry-leading speakers will: - Share insights into pre-clinical/clinical success stories - Reflect on ongoing obstacles to overcome like toxicity & therapeutic resistance - Discuss alignment with regulatory expectations - Strategize ways forward with innovative approaches like bispecific ADCs & micellar encapsulation - Explore improvements to bispecific design through next generation targeting and novel bispecific formats See all sessions/speakers here: https://ter.li/f5zs1l This is a 3-day meeting designed to maximize learning, collaboration and networking to provide the tools to push bispecific antibodies to the forefront of oncology-indication treatments and beyond. We hope to welcome you in Boston soon!
